Clinical trials: Renal Allograft Recipients
Kidney Transplantation, Chronic Allograft Nephropathy
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
The purpose of this study is to see if kidney function can be improved during transplants by giving the drug Thymoglobulin with delayed cyclosporine treatment instead of initial cyclosporine treatment.
- Trial name
- NCT00007787
- Testing
- Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study
Endothelial lesions within the transplanted kidney are a major determinant of chronic allograft nephropathy. Epoxyeicosatrienoic acids (EETs) are endothelium-derived hyperpolarizing factors with anti-inflammatory…
- Trial name
- TRANSPLANTEETs (NCT02555566)
- Testing
- Blood sampling, flow-mediated distal stimulation of the forearm radial artery by cutaneous heating
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Rouen
HBsAg(+) Donor Kidney Allograft, HBsAg(-) Donor Kidney Allograft
Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients
To determine the safety of using kidney organ from hepatitis B surface antigen positive donor, the author conducted the single-center, prospective study of the use of these kidneys for recipients who have protective level of…
- Trial name
- NCT02044588
- Testing
- HBsAg positive kidney allograft donor
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Transplant Rejection, Renal Transplantation
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
Sirolimus, 1 mg, white, triangular tablets (Rapamune®) was approved on 03 April 2007 in China for prophylaxis of organ rejection in renal transplantation.
- Trial name
- NCT01236378
- Testing
- Sirolimus
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Pfizer
Kidney Transplantation
An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients
This observational survey study will capture all renal transplant patients in Serbia who are currently receiving CellCept (mycophenolate mofetil) as part of their immunosuppressive protocol.
- Trial name
- NCT01707550
- Where
- 3 sites in Serbia
- Volunteers
- 414 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type I
Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant.
- Trial name
- NCT00888628
- Testing
- Purified Pancreatic Islets, Etanercept
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Chronic Allograft Nephropathy, Chronic Kidney Disease
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the neck.
- Conditions
- Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism
- Trial name
- NCT00975000
- Testing
- Cinacalcet
- Where
- 51 sites in United States, Australia and 9 more
- Volunteers
- 114 people
- Sponsor
- Amgen
Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors
SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients
This clinical trial investigates whether 18 months of daily SGLT2i (10 mg Forxiga) preserves kidney function and evaluates safety, based on eGFR changes and adverse event occurrence in non-diabetic kidney transplant recipients.
- Conditions
- Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial
- Trial name
- SGL-TX-GFR (NCT07143773)
- Testing
- SGLT-2 inhibitor
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- Odense University Hospital
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Kidney Transplant
Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants
Evaluate the incidence of acute rejection at 12 months after transplantation in subjects receiving induction therapy with cyclosporine microemulsion (CsA) and Rapamune followed by CsA dose reduction (Phase I) with subjects…
- Trial name
- NCT00257387
- Testing
- Cyclosporine
- Volunteers
- 120 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplantation
Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus
To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients.
- Trial name
- NCT00507793
- Testing
- Sirolimus, Cyclosporine
- Volunteers
- 385 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Validation of Gene Expression Markers of Renal Allograft Functional Decline
The purpose of this study is to determine if certain genes found in a kidney biopsy performed at one-year post transplant can predict which transplanted kidneys will have decreased kidney function within five years…
- Trial name
- NCT01782586
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Delayed Graft Function
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function.
- Trial name
- VARVARA (NCT05907096)
- Testing
- ARGX-117
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 103 people
- Sponsor
- argenx
Organ Transplantation
Belatacept Post Depletional Repopulation to Facilitate Tolerance
Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney.
- Trial name
- NCT00565773
- Testing
- Belatacept, Sirolimus, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allan D Kirk, MD, PhD
Kidney Transplant
MMF vs. AZA for Kidney Transplantation
The Mycophenolate Steroid Sparing (MYSS) study demonstrated that, in the setting of a maintenance immunosuppressive regimen without steroids, mycophenolate mofetil (MMF) and azathioprine (AZA) provided the same efficacy in…
- Trial name
- ATHENA (NCT00494741)
- Testing
- mycophenolate mofetil, azathioprine
- Where
- 6 sites in Italy
- Volunteers
- 233 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Renal Transplantation
Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)
The purpose of this observational study is to examine the clinical outcomes of the use of sirolimus as base therapy in kidney allograft recipients from Expanded Criteria Donors (ECD) under conditions of routine clinical practice.
- Trial name
- NCT00697112
- Testing
- Sirolimus
- Where
- 8 sites in Argentina
- Volunteers
- 53 people
- Sponsor
- Pfizer
Graft Rejection, Kidney Failure
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.
- Conditions
- Graft Rejection, Kidney Failure, Kidney Transplantation
- Trial name
- NCT00273871
- Testing
- Cyclosporin or tacrolimus
- Volunteers
- 190 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant, Solid Tumor, Solid Tumor Cancer
- Trial name
- NCT07100925
- Testing
- tolododekin alfa
- Sponsor
- Ankyra Therapeutics, Inc
Kidney Transplant
A Study Of CP-690,550 In Stable Kidney Transplant Patients
This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients.
- Trial name
- NCT01710033
- Testing
- CP-690,550 5 mg BID, CP-690,550 15 mg BID, CP-690,550 30 mg BID
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer